Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human embryonic stem cell based neuro-developmental toxicity assay: response to valproic acid and carbamazepine exposure

ABSTRACT: Here we studied the effects of anticonvulsant drug exposure in a human embryonic stem cell (hESC) based neuro- developmental toxicity test (hESTn). During neural differentiation the cells were exposed, for either 1 or 7 days, to non-cytotoxic concentration ranges of valproic acid (VPA) or carbamazepine (CBZ), anti-epileptic drugs known to cause neurodevelopmental toxicity.

ORGANISM(S): Homo sapiens

PROVIDER: GSE64123 | GEO | 2015/06/01

SECONDARY ACCESSION(S): PRJNA270221

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

gene expression profile of CBZ treated mice

Project description:Carbamazepine (CBZ) is widely used in the treatment of neuropsychiatric disorders as an anticonvulsant. A recent report revealed that CBZ has an anti-fibrotic effect on the livers of α1-antitrypsin-deficient mice, raising the possibility of a hepatology-related therapeutic use for the drug.Given the fact that CBZ has complicated pharmacokinetic properties, to comprehensively understand the its mechanism of action, we performed microarray analysis of the mouse liver tissues 2 hours after CBZ administration.

2013-05-17 | GSE46731 | GEO

gene expression profile of CBZ treated mice

Project description:Carbamazepine (CBZ) is widely used in the treatment of neuropsychiatric disorders as an anticonvulsant. A recent report revealed that CBZ has an anti-fibrotic effect on the livers of M-NM-11-antitrypsin-deficient mice, raising the possibility of a hepatology-related therapeutic use for the drug.Given the fact that CBZ has complicated pharmacokinetic properties, to comprehensively understand the its mechanism of action, we performed microarray analysis of the mouse liver tissues 2 hours after CBZ administration. The mice were orally administered 250 mg/kg of CBZ or DMSO and examined for the gene expression 2 hours later; 3 mice per group.

2013-05-17 | E-GEOD-46731 | biostudies-arrayexpress

Transcription profiling of human chronic lymphocytic leukemia cells treated with valproic acid

Project description:Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have recently been proposed as potential new therapies for hematological malignancies. Chronic Lymphocytic Leukemia (CLL) remains incurable despite the introduction of new treatments. CLL cells are characterized by an apoptosis defect rather than excessive proliferation, but proliferation centers have been found in organs such as bone marrow and lymph nodes. Here, we investigated gene expression modifications in CLL cells following treatment with valproic acid (VPA), a well-tolerated anti-epileptic drug with HDAC inhibitory activity. Experiment Overall Design: CLL cells obtained from 14 patients were treated in vitro with a concentration of 1mM VPA for 4 hours. VPA effects on gene expression were thereafter studied using Affymetrix technology

2009-09-17 | E-GEOD-14973 | biostudies-arrayexpress

Reduced adult neurogenesis and neuronal abnormalities in the hippocampus underlie cognitive deficiency following prenatal administration of the anti-epileptic drug valproic acid

Project description:Prenatal exposure to valproic acid, an established anti-epileptic drug, has been reported to impair postnatal cognitive function of children from epileptic mothers. Nevertheless, its pathology and proper treatment to minimize the effects remain unknown. In mice, we found that the postnatal cognitive function impairment was mainly caused by a reduction of adult neurogenesis and abnormal neuronal features in the hippocampus, which could be ameliorated by voluntary running. Pregnant mice received an oral administration of methylcellulose (MC), valproic acid (VPA) or valpromide (VPM) once a day on three consecutive embryonic days (E) 12.5, E13.5, and E14.5 and were sampled 3hr after the last administration (E14.5), at E18.5, and at 12 weeks of age.

2015-12-08 | E-GEOD-42904 | biostudies-arrayexpress

Identification differentially expressed genes upon valproic acid treatment

2011-07-13 | GSE30517 | GEO

Antileukemic activity of valproic acid in chronic lymphocytic leukemia cells defined by microarray analysis

2009-08-24 | GSE14973 | GEO

Identification differentially expressed genes upon valproic acid treatment

Project description:The goal of this study is to define genes that are differentially expressed in Down syndrome leukemic blasts after treatment with valproic acid (VPA) Here we report the identification gene sets that are downregulated in Down syndrome leukemic cell lines after exposure to valproic acid (VPA) CMK and CMY cells were treated with VPA for 24h and 48h with 1mM or 2mM VPA. Their gene expression profile was compared against the untreated control.

2011-07-12 | E-GEOD-30517 | biostudies-arrayexpress

Transcriptome analysis of gilthead sea bream (Sparus aurata) brain after exposure to environmental concentrations of human pharmaceuticals

Project description:A gilthead sea bream (Sparus aurata) microarray platform was developed to identify brain gene expression profiles in response to environmental concentrations of human pharmaceuticals. Comparative analysis of gene expression profiles was conducted among brain of gilthead seabream exposed to Acetaminophen (APAP; analgesic), Carbamazepine (CBZ; anti-epileptic) and Atenolol (AT; β-blocker). All groups of samples were also compared with brain of control individuals.

2014-05-22 | E-GEOD-38195 | biostudies-arrayexpress

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

Project description:Transcriptional profiling of human placenta-derived JEG-3 cell line comparing vehicle control with 7.38 mM of valproic acid(VPA)-treated JEG-3 cells for 48 hr. 7.38 mM valproic acid(VPA) induced the 30% inhibiotion of JEG-3 cell proliferation, G1 phase cell cycle arrest and the reduction of cell size. The Goal was to analyze the mechanism of valproic acid-induced adverse effects in placental cells. Two-condition experiment, JEG-3 cells vs. valproic acid(VPA)-treated JEG-3 cells. Biological replicates: 3 control replicates, 3 VPA-treated replicates.

2012-10-11 | E-GEOD-41441 | biostudies-arrayexpress

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

2012-10-11 | GSE41441 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data